FibroScan / VCTE: What Your Number Changes About Your Treatment

What FibroScan / VCTE Actually Measures

FibroScan sends a low-frequency vibration pulse into liver tissue and measures how fast the shear wave travels. Stiffer livers, scarred by fibrosis, conduct that wave faster. The machine converts wave speed into a kPa value in about 10 minutes without a needle. The companion controlled attenuation parameter (CAP) score, reported in decibels per meter (dB/m), estimates hepatic fat content simultaneously.

The test is registered as VCTE (vibration-controlled transient elastography) in clinical literature. A reliable exam requires at least 10 valid shots, an interquartile range/median ratio below 30%, and ideally a fasting state of at least 2 hours. Obesity (BMI above 30) can reduce probe penetration; the XL probe addresses this for most patients.

Why Liver Stiffness Matters More Than a Blood Panel Alone

Standard liver enzymes, ALT and AST, can be normal even in advanced fibrosis. A 2022 analysis in Hepatology found that up to 25% of patients with biopsy-confirmed F3 fibrosis had ALT values within the normal laboratory reference range. VCTE catches what blood tests miss.

The Fibroscan result also predicts clinical outcomes independently of other markers. A landmark cohort study published in Journal of Hepatology (N=14,397) showed that liver stiffness above 9.6 kPa was associated with a 2.9-fold increase in liver-related events over a median 4.3 years of follow-up, after adjusting for age, sex, and BMI. [1]

How the CAP Score Adds Context

CAP scores below 248 dB/m suggest <11% hepatic fat (S0). Scores of 248-267 dB/m indicate mild steatosis (S1). Values of 268-279 dB/m correspond to moderate steatosis (S2), and scores above 280 dB/m reflect severe steatosis (S3). A patient with a kPa of 7.5 and a CAP of 310 dB/m has heavy fat accumulation but minimal fibrosis, a profile that calls for metabolic intervention rather than antifibrotic therapy. [2]

The kPa Fibrosis Scale: F0 Through F4

The fibrosis staging system most commonly used in VCTE interpretation maps kPa ranges to histologic fibrosis grades. These cutoffs vary slightly by etiology (MASLD vs. Alcohol vs. Viral hepatitis), but the values below apply to metabolic-associated steatotic liver disease (MASLD), the most common indication for FibroScan in a telehealth GLP-1 or TRT practice. [3]

F0-F1 (No to Mild Fibrosis): kPa Below 8.0

A result below 8.0 kPa means the liver shows no significant scarring. Lifestyle modification, weight management, and optimization of metabolic risk factors (glucose, triglycerides, blood pressure) are the standard of care. No FDA-approved antifibrotic drug is indicated at this stage. Repeat VCTE is appropriate in 12 months if metabolic syndrome features are present, or in 24 months if the metabolic profile is otherwise clean. [4]

F2 (Moderate Fibrosis): kPa 8.0 to 9.6

F2 is where clinical urgency increases. The 2023 American Association for the Study of Liver Diseases (AASLD) guidance states that patients with confirmed MASH and F2 fibrosis meet the histologic threshold for pharmacologic intervention. Resmetirom's key MAESTRO-NASH trial enrolled patients with F1-F3 fibrosis, but the FDA label for resmetirom specifically covers non-cirrhotic MASH with moderate to advanced fibrosis (F2-F3). [5]

A patient with a kPa of 8.5, a CAP score above 280 dB/m, and elevated ALT should be evaluated for resmetirom eligibility. GLP-1 receptor agonists such as semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) have shown meaningful reductions in hepatic steatosis and early fibrosis in this range. The ESSENCE trial (NCT04822181) is evaluating semaglutide 2.4 mg specifically in MASH with F2-F3 fibrosis, with results expected in 2025. [6]

F3 (Advanced Fibrosis): kPa 9.7 to 12.0

F3 is the most treatment-intensive non-cirrhotic stage. Both resmetirom eligibility and hepatology co-management are standard at this threshold. The MAESTRO-NASH trial (N=966) tested resmetirom 80 mg and 100 mg daily in patients with biopsy-confirmed MASH and F1-F3 fibrosis. At 52 weeks, 26% of patients on resmetirom 100 mg achieved fibrosis improvement by at least one stage versus 14% on placebo (P<0.001). [7]

The HealthRX clinical team applies a three-signal rule at F3: (1) confirm MASH diagnosis with at least one non-invasive biomarker such as the FIB-4 index or NIS4 score, (2) initiate or optimize GLP-1 therapy for concurrent weight and glycemic targets, and (3) refer to hepatology for shared management of resmetirom initiation. This approach aligns with the FDA label, which requires MASH confirmation before prescribing.

F4 (Cirrhosis): kPa Above 13.0

Cirrhosis changes the treatment calculus entirely. Resmetirom is contraindicated in decompensated cirrhosis (Child-Pugh B and C). For compensated cirrhosis (Child-Pugh A), prescribing resmetirom is off-label and carries higher scrutiny for thyroid hormone-related adverse effects given that resmetirom acts as a thyroid hormone receptor beta agonist. [8]

At F4, the focus shifts to surveillance: hepatocellular carcinoma (HCC) screening with ultrasound every 6 months per AASLD guidelines, esophageal variceal screening by upper endoscopy, and MELD score tracking. GLP-1 therapy may still be used for weight and glycemic control in Child-Pugh A cirrhosis, though dose titration should be more conservative given altered drug metabolism.

How FibroScan Results Change Specific Prescribing Decisions

Resmetirom (Rezdiffra): The First Direct Antifibrotic Approval

The FDA approved resmetirom on March 14, 2024, making it the first drug ever approved specifically for MASH. The label indication is: "non-cirrhotic adults with MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." [9]

The approved doses are 80 mg daily for patients weighing <100 kg and 100 mg daily for patients at or above 100 kg. Both doses must be taken with food. The most common adverse effects reported in MAESTRO-NASH were nausea (17.8% on 100 mg vs. 10.4% placebo) and diarrhea (16.7% vs. 10.9% placebo). [7]

FibroScan kPa is the primary gating criterion in practice because liver biopsy, while still the gold standard the FDA references in label language, is rarely performed in routine outpatient settings. A VCTE result between 9.7 and 12.0 kPa, combined with a CAP score above 268 dB/m and elevated liver enzymes, provides strong non-invasive evidence for F2-F3 MASH. Clinicians using this approach should document the rationale clearly in the chart.

GLP-1 Receptor Agonists and Hepatic Outcomes

Semaglutide 0.4 mg subcutaneous daily (a dose studied in the NASH-specific NEJM trial by Newsome et al., N=320) produced NASH resolution in 59% of patients versus 17% on placebo at 72 weeks, though fibrosis improvement did not reach statistical significance in that cohort. [10]

Higher doses used in obesity management show more promising fibrosis signals. Tirzepatide 10 mg and 15 mg weekly reduced liver fat by up to 50% from baseline in the SURMOUNT-1 sub-analysis (N=2,539), with reductions in ALT consistent with fibrosis regression. [11] For a patient with F2-F3 fibrosis who cannot tolerate or afford resmetirom, escalating to the highest tolerated GLP-1 dose is the most evidence-supported alternative currently available.

Testosterone Replacement Therapy and VCTE

Men on testosterone replacement therapy (TRT) require VCTE monitoring because androgen excess may worsen hepatic steatosis in some metabolic phenotypes, while testosterone deficiency itself is independently associated with MASLD. A 2023 observational study (N=428) in Andrology found that men with hypogonadism and MASLD who achieved testosterone levels in the mid-normal range (450-700 ng/dL) showed a 1.2 kPa mean reduction in liver stiffness at 12 months, compared with no change in untreated controls. [12]

HealthRX recommends baseline VCTE for any patient starting TRT who has a BMI above 30, type 2 diabetes, or metabolic syndrome features. Repeat VCTE at 6 months assesses the directional effect.

How to Lower Your FibroScan Number

Liver fibrosis is partially reversible. Documented regression from F3 to F2 or F2 to F1 is achievable with sustained intervention. The main levers are weight loss, glycemic control, alcohol elimination, and, where indicated, pharmacotherapy.

Weight Loss Targets

A 10% or greater reduction in body weight is associated with fibrosis regression in MASH. The LEAN trial (N=52) demonstrated that liraglutide 1.8 mg daily produced NASH resolution in 39% of patients versus 9% on placebo, with a trend toward fibrosis improvement. [13] The magnitude of hepatic benefit correlates directly with the percentage of body weight lost, not simply with the drug mechanism.

For patients using semaglutide 2.4 mg, the STEP-1 trial (N=1,961) showed 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. [14] A 14.9% weight reduction in a 100 kg patient (roughly 15 kg of loss) is well above the 10% threshold associated with fibrosis regression.

Glycemic Control

Hemoglobin A1c above 8.0% is independently associated with faster fibrosis progression. The AACE 2022 clinical practice guidelines state that optimizing glycemic control to an A1c of 6.5-7.0% in patients with MASLD reduces hepatic inflammation and may slow fibrosis progression. [15] Metformin does not directly treat MASH fibrosis, but pioglitazone 30-45 mg daily has the strongest evidence among antidiabetic agents for fibrosis regression, with a number-needed-to-treat of approximately 4 for one-stage fibrosis improvement over 18 months in the PIVENS trial (N=247). [16]

Alcohol and Medication Review

Any alcohol intake accelerates fibrosis in the setting of MASLD. The combination of metabolic liver disease plus even moderate alcohol use creates a synergistic injury pattern described in the 2023 AASLD guidance as MetALD. Medications that may worsen steatosis include corticosteroids, amiodarone, tamoxifen, and methotrexate. A medication reconciliation step is warranted before repeating VCTE to ensure the number reflects intrinsic liver health rather than a drug effect.

How to Interpret a Rising FibroScan Number

A kPa increase of 2.0 or more between scans (when technical quality is confirmed) signals progression. The differential includes worsening MASLD, new or increased alcohol use, a drug-induced effect, congestive heart failure causing hepatic congestion, or disease of a different etiology entirely.

Before attributing a rising kPa to MASLD progression, the clinical team should confirm fasting status at both exams, rule out right-heart pathology with a BNP or echocardiogram if clinically appropriate, and assess for any interim medication changes. Post-meal scans can transiently raise liver stiffness by 1.0-2.5 kPa due to increased portal blood flow.

A confirmed rise from below 8.0 kPa to above 9.7 kPa over 12 months warrants hepatology referral regardless of symptom status.

Normal FibroScan / VCTE Range: A Reference Table

| Fibrosis Stage | kPa Range (MASLD) | Clinical Meaning | Treatment Implication | |---|---|---|---| | F0-F1 | <8.0 kPa | No to mild fibrosis | Lifestyle, metabolic optimization | | F2 | 8.0-9.6 kPa | Moderate fibrosis | GLP-1 escalation; resmetirom eligible | | F3 | 9.7-12.0 kPa | Advanced fibrosis | Resmetirom first-line; hepatology co-management | | F4 | >13.0 kPa | Cirrhosis | HCC surveillance; varices screening; resmetirom contraindicated in decompensated disease |

CAP score reference values: S0 <248 dB/m, S1 248-267 dB/m, S2 268-279 dB/m, S3 >280 dB/m. [2]

Monitoring Frequency on Active Treatment

Once a patient is prescribed resmetirom, the MAESTRO-NASH protocol measured outcomes at 52 weeks. In clinical practice, the HealthRX medical team recommends repeating VCTE at 6 months to detect early response and at 12 months to assess fibrosis-stage change. A one-stage improvement by 12 months supports continuing the current regimen. Stable kPa with no improvement by 18 months may prompt biopsy to confirm true histologic response before extending the prescription further.

For patients on GLP-1 therapy without resmetirom, repeat VCTE at 12 months after achieving a stable maintenance dose gives the most interpretable signal, since weight loss kinetics with semaglutide and tirzepatide plateau between 52 and 72 weeks. [14]

Patients with F0-F1 and no active pharmacotherapy should repeat VCTE every 12-24 months if metabolic syndrome is present, and every 3 years if metabolic markers are well controlled. The European Association for the Study of the Liver (EASL) 2021 clinical practice guidelines support this interval-based monitoring approach. [17]